Gilead Stock News

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among […]

Shoker Investment Counsel Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,837 shares of the biopharmaceutical companys stock after buying an additional 1,415 shares during the period. Shoker Investment Counsel Inc.s holdings []

Howland Capital Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,536 shares of the biopharmaceutical companys stock after selling 1,669 shares during the period. Howland Capital []

Dan Genter, CEO and chief investment officer at RNC Genter Capital, joins 'The Exchange' to discuss his top stock picks.

Plimoth Trust Co. LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,505 shares of the biopharmaceutical companys stock after selling 747 shares during the period. Plimoth Trust Co. LLCs holdings []

Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.

Wells Fargo & Company began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Wednesday morning, The Fly reports. The firm issued an equal weight rating on the biopharmaceutical companys stock. A number of other brokerages have also recently issued reports on GILD. BMO Capital Markets upgraded Gilead Sciences from a []

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Investment analysts at Wells Fargo & Company began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Wednesday, The Fly reports. The firm set an equal weight rating on the biopharmaceutical companys stock. A number of other equities analysts also recently weighed in on the stock. Royal Bank of Canada reissued a []

VANCOUVER, BC , Dec. 8, 2021 /PRNewswire/ -- USA News Group - Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit nearly $310 billion by 2030, according to Allied Analytics . Over the past decade, cancer drug revenues increased 70%, according to a retrospective analysis . Last December, biotechs working on breast cancer treatments saw their shares soar . This year has continued that momentum, with multiple biotech companies driving progress in the fight against cancer, including from Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ), Incyte Corporation (NASDAQ: INCY ), BriaCell Therapeutics Corp. (NASDAQ: BCTX ), Gilead Sciences, Inc. (NASDAQ: GILD ), and Eli Lilly and Company (NYSE: LLY ). Coming up between December 11-14, 2021 , Oncolytics Biotech Inc. (NASDAQ: ONCY ) (TSX: ONC ) will give an update at the upcoming 63 rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) on its Phase II Triple-Negative Breast Cancer Trial—known as the IRENE study, which is evaluating the company''s flagship product pelareorep, an immunotherapeutic agent that turns "cold" tumors "hot", in combination with the anti-PD-1 checkpoint inhibitor, retifanlimab, from Incyte Corporation (NASDAQ: INCY ).

The global Liver Fibrosis Treatment market is expected to reach US$ 32.6 Billion by 2027, with a CAGR of 13.1% from 2021 to 2027. Treatment choices for liver fibrosis are largely determined by the disease''s underlying cause. To lessen the

Fernwood Investment Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 32,537 shares of the biopharmaceutical companys stock after selling 2,740 shares during the period. Fernwood Investment Management LLCs holdings in Gilead Sciences []

Arkadios Wealth Advisors raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 37.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,493 shares of the biopharmaceutical companys stock after acquiring an additional 676 shares during the period. Arkadios Wealth Advisors []

Gilead Sciences is facing multiple headwinds, but there may be hope for the biotech company.